KYMR — Kymera Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.99bn
- $8.30bn
- $39.21m
Brief: Kymera Therapeutics Q1 EPS USD -0.71
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Kymera up after FDA fast-track for asthma pill
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman
U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
U.S. STOCKS ON THE MOVE-Marvell Technology, Tempus AI, Energy Vault
U.S. STOCKS ON THE MOVE-Tesla, CoreWeave, Kymera
Kymera rises as Gilead pays $45 million for experimental cancer drug
Brief: Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Kymera Q4 revenue misses expectations, net loss widens
Brief: Kymera Therapeutics Q4 EPS USD -0.97
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite
Brief: Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader
U.S. STOCKS ON THE MOVE-Robinhood Markets, Cannabis stocks, Hyatt Hotels
U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
U.S. STOCKS ON THE MOVE-Netflix, Amazon, Palo Alto Networks